[1]王文辉,李宝华,李 雷,等.载药微球治疗中期原发性肝癌25例[J].介入放射学杂志,2021,30(03):270-274.
 WANG Wenhui,LI Baohua,LI Lei,et al.CalliSpheres-loaded microspheres for the treatment of mid-stage hepatocellular carcinoma: analysis of its efficacy and safety in 25 patients[J].journal interventional radiology,2021,30(03):270-274.
点击复制

载药微球治疗中期原发性肝癌25例()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年03
页码:
270-274
栏目:
临床研究
出版日期:
2021-03-29

文章信息/Info

Title:
CalliSpheres-loaded microspheres for the treatment of mid-stage hepatocellular carcinoma: analysis of its efficacy and safety in 25 patients
作者:
王文辉 李宝华 李 雷 李双喜 杨旭军 许方裕
Author(s):
WANG Wenhui LI Baohua LI Lei LI Shuangxi YANG Xujun XU Fangyu.
Department of Intervention, First Hospital of Lanzhou University, Gansu Province 730000, China
关键词:
【关键词】 原发性肝癌 经肝动脉化疗栓塞术 载药微球
文献标志码:
A
摘要:
【摘要】 目的 评估采用国产载药微球(CalliSpheres)TACE治疗中期原发性肝癌的安全性及近期临床疗效。方法 25例经临床确诊的中期肝癌患者,在行TACE治疗中使用CalliSpheres载药微球进行栓塞,并对患者基本资料、影像随访、栓塞治疗后的不良反应、并发症和临床疗效等进行总结和分析。结果 25例患者随访6~18个月;采用改良实体瘤疗效评价标准(mRECIST),结果显示DEB-TACE术后3个月客观缓解率(ORR)为76%,疾病控制率(DCR)为88%;6个月ORR为56%,DCR为68%;9个月ORR为47.4%,DCR为63.2%;中位疾病无进展生存期(mPFS)为9.0个月;6个月、1年生存率分别为92%、76%;术后平均住院时间为(7.0±1.6)d;术后1 d肝功能显示ALT、AST升高,3 d TBIL达最高值,之后降至正常,与术前比较差异有统计学意义(P<0.05);ALB与术前比较降低,差异有统计学意义(P<0.05);术后所有患者出现不同程度疼痛,部分患者出现发热等栓塞后综合征,其中1例患者出现肝脓肿,经抗感染和经皮肝穿刺引流治疗后好转。结论 使用CalliSpheres载药微球栓塞治疗中期肝癌的近期疗效及安全性均较好,远期疗效仍需扩大样本量及国内多中心随机对照研究观察获得。

参考文献/References:

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394- 424.
[2] European Association for the Study of the Liver. Corrigendum to EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2019, 70: 817.
[3] 吴孟超,汤钊猷,刘允怡,等. 原发性肝癌诊疗规范(2019年版)[J]. 中华消化外科杂志, 2020, 19:1-2.
[4] Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics[J]. J Hepatol, 2007, 46: 474- 481.
[5] Fuchs K, Duran R, Denys A, et al. Drug- eluting embolic microspheres for local drug delivery:state of the art[J]. J Control Release, 2017, 262: 127-138.
[6] Han S, Zhang X, Zou L, et al. Does drug- eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis[J]. PLoS One, 2014, 9: e102686.
[7] Au JS, Frenette CT. Management of hepatocellular carcinoma: current status and future directions[J]. Gut Liver, 2015, 9: 437- 448.
[8] 王应强 李向莲 李幼平,等.全球肿瘤介入治疗的研究现状[J]. 中国循证医学杂志, 2013, 13:1060-1072.
[9] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53: 1020-1022.
[10] Jordan O, Denys A, De Baere T, et al. Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan[J]. J Vasc Interv Radiol, 2010, 21: 1084-1090.
[11] Baur J, Ritter CO, Germer CT, et al. Transarterial chemoemboli-zation with drug- eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma[J]. Hepat Med, 2016, 8: 69-74.
[12] 陈 元, 魏晓艳,曹 凯, 等. 药物洗脱微球经肝动脉化疗栓塞术治疗中晚期原发性肝癌的疗效[J]. 中国肿瘤临床与康复, 2017, 24:711-714.
[13] Lee M, Chung JW, Lee KH, et al. Korean multicenter registry of transcatheter arterial chemoembolization with drug- eluting embolic agents for nodular hepatocellular carcinomas: six- month outcome analysis[J]. J Vasc Interv Radiol, 2017, 28: 502-512.
[14] 欧盛秋,陈祖毅,马亦龙,等. 阿霉素载药微球与传统的碘化油经导管动脉化疗栓塞术治疗原发性肝癌疗效的Meta分析[J].中国介入影像与治疗学, 2014, 11:712-716.
[15] 尹伟利,连 佳,肖时湘,等. 载药微球与传统碘化油经肝动脉化疗栓塞治疗不可切除肝癌疗效比较的Meta分析[J]. 临床肝胆病杂志, 2019, 35:1270-1274.
[16] 曹国洪,王 凯,李佳琪,等. CalliSpheres?誖载药微球经动脉导管化疗栓塞治疗肝癌患者的有效性及安全性分析[J]. 中国介入影像与治疗学, 2018, 15:42- 46.
[17] 姜 松,李桂杰,周祝谦,等. CalliSpheres载药栓塞微球治疗中晚期肝癌临床效果评价[J]. 中华介入放射学电子杂志, 2017, 5:174-178.
[18] 刘 金,曹 刚,张根山,等. 国产CalliSpheres载药微球治疗原发性肝癌12例[J]. 介入放射学杂志, 2017, 26: 993-998.
[19] Peng JW, Lin GN, Xiao JJ, et al. Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy[J]. Asia Pac J Clin Oncol, 2012, 8: 356-361.
[20] Malagari K, Kiakidis T, Pomoni M,et al. Phannacokinetics, safety, and efficacy of chemoembolization witfi doxorabicin-loaded tightly calibrated small microspheres in patients widi hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2016,39: 1379-1391 .

相似文献/References:

[1]高 嵩,朱旭,杨仁杰,等. TACE联合奥沙利铂、氟尿嘧啶、亚叶酸钙肝动脉化疗治疗中晚期原发性肝癌[J].介入放射学杂志,2012,(05):377.
 ,,et al. TACE combined with hepatic arterial infusion chemotherapy using oxaliplatin, 5fluorouracil and folinic acid for intermediate and advanced hepatocellular carcinomas[J].journal interventional radiology,2012,(03):377.
[2]程洪涛,郭晨阳,黎海亮,等.TACE联合射频消融治疗原发性肝癌疗效的影响因素分析[J].介入放射学杂志,2012,(03):216.
 ,,et al.TACE combined with CTguided percutaneous radiofrequency ablation for the treatment of primary hepatocellular carcinomas: an analysis of factors affecting the therapeutic result [J].journal interventional radiology,2012,(03):216.
[3]张晓前,郭 鹏,党之俊,等.金龙胶囊联合介入疗法治疗原发性肝癌临床观察[J].介入放射学杂志,2012,(03):249.
 ,,et al.Kinglong capsules combined with interventional therapy for hepatocellular carcinomas: clinical observation [J].journal interventional radiology,2012,(03):249.
[4]姚红响,陈根生,诸葛英,等.肝动脉化疗栓塞联合CT引导射频消融序贯治疗中小肝癌的临床应用[J].介入放射学杂志,2012,(04):301.
 ,,et al.Sequential treatment with TACE and CTguided RFA for small and moderate sized HCC [J].journal interventional radiology,2012,(03):301.
[5]姚全军,胡鸿涛,黎海亮,等.C臂CT成像在乏血供原发性肝癌诊疗中的临床应用[J].介入放射学杂志,2012,(04):305.
 ,,et al.The clinical application of C arm CT imaging in diagnosing and treating hypovascular primary hepatic carcinomas [J].journal interventional radiology,2012,(03):305.
[6]刘 昕,吕维富,鲁 东,等. 动脉介入栓塞治疗肝癌破裂出血[J].介入放射学杂志,2012,(07):586.
 LIU Xin,LV Wei- fu,LU Dong,et al. Interventional treatment of hepatic bleeding due to spontaneous rupture of hepatocellular carcinoma[J].journal interventional radiology,2012,(03):586.
[7]张志良,杨学东,温阿明,等. 经动脉化疗栓塞联合伽玛刀治疗原发性肝癌的疗效评价[J].介入放射学杂志,2012,(07):596.
 ZHANG Zhi- liang,YANG Xue- dong,WEN A-ming,et al. Evaluation of TACE combined with gamma?蛳 knife radiotherapy for primary hepatocellular carcinoma[J].journal interventional radiology,2012,(03):596.
[8]赵许亚,周 石.TACE联合经皮瘤内注射碘油吡柔比星乳剂治疗中晚期肝癌疗效分析[J].介入放射学杂志,2012,(08):675.
 ZHAO Xu- ya,ZHOU Shi.. Transcatheter artery chemoembolization combined with percutaneous intratumoral injection of Lipiodol emulsion of pirarubicin for advanced hepatocellular carcinomas: an analysis of clinical efficacy[J].journal interventional radiology,2012,(03):675.
[9]王少雷,李 森,魏 宏,等.奥沙利铂与吡喃阿霉素介入治疗原发性肝癌的比较研究[J].介入放射学杂志,2012,(09):738.
 WANG Shao- lei,LI Sen,WEI Hong,et al. Interventional chemoembolization therapy of primary hepatocellular carcinoma: a comparative study between oxaliplatin and therarubicin[J].journal interventional radiology,2012,(03):738.
[10]骆俊朋,胡鸿涛,郭晨阳,等.吉西他滨热化疗灌注联合卡铂化疗栓塞治疗原发性肝癌临床应用研究[J].介入放射学杂志,2013,(06):470.
 LUO Jun? peng,HU Hong? tao,GUO Chen? yang,et al. Hyperthermochemotherapy by using heated gemcitabine perfusion combined with transcatheter arterial chemoembolization of carboplatin for primary liver carcinomas[J].journal interventional radiology,2013,(03):470.
[11]姚 征,陈玉堂,罗 君,等.131I美妥昔单抗注射液联合TACE治疗76例中晚期原发性肝癌的疗效及安全性研究[J].介入放射学杂志,2016,(01):65.
 YAO Zheng,CHEN Yu- tang,LUO Jun,et al.131I- labeled metuximab combined with transcatheter arterial chemoembolization for advanced primary hepatic carcinomas: evaluation of safety and effect in 76 patients[J].journal interventional radiology,2016,(03):65.

备注/Memo

备注/Memo:
(收稿日期:2020-10-11)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2021-03-25